1. Чучалин А.Г., Синопальников А.И., Страчунский Л.С. и др. Внебольничная пневмония у взрослых: практические рекомендации по диагностике, лечению и профилактике. Клин. микробиол. антимикроб. химиотер. 2006; 8: 54–86.
2. Renaud B, Coma E, Labarere J et al. Routine use of the Pneumonia Severity Index for guiding the site-of-treatment decision of patients with pneumonia in the emergency department: a multicenter, prospective, observational, controlled cohort study. Clin Infect Dis 2007; 44: 41–9.
3. Pomilla PV, Brown RB. Outpatient treatment of community-acquired pneumonia in adults. Arch Intern Med 1994; 154: 1793–802.
4. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 2001; 56 (Suppl. 4): IV1–64.
5. Woodhead M, Blasi F, Ewig S et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138–80.
6. Sanguinetti CM, De Benedetto F, Donner CF. GP management of community-acquired pneumonia in Italy: the ISOCAP study. Monaldi Arch Chest Dis 2005; 63: 23–9.
7. Mandell LA, Wunderink RG, Anzueto A et al. Infectious diseases society of america/american thoracic society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl. 2): S27–72.
8. Yealy DM, Auble TE, Stone RA et al. Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial. Ann Intern Med 2005; 143: 881–94.
9. Pechere JC, Hughes D, Kardas P et al. Non-compliance with antibiotic therapy for acute community infections: a global survey. Int J Antimicrob Agents 2007; 29: 245–53.
10. Kardas P. Comparison of patient compliance with once-daily and twice-daily antibiotic regimens in respiratory tract infections: results of a randomized trial. J Antimicrob Chemother 2007; 59: 531–6.
11. Schrag SJ, Pena C, Fernandez J et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. Jama 2001; 286: 49–56.
12. Tleyjeh IM, Tlaygeh HM, Hejal R et al. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2006; 42: 788–97.
13. File TM, Jr. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin Infect Dis 2004; 39 (Suppl. 3): S159–64.
14. Chastre J, Wolff M, Fagon JY et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290: 2588–98.
15. Riedel S, Beekmann SE, Heilmann KP et al. Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 2007; 26: 485–90.
16. Doern GV. Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin Infect Dis 2001; 33 (Suppl. 3): S187–92.
17. Ree GH, Davis M. Treatment of lobar pneumonia in Papua New Guinea: short course chemotherapy with penicillin or chloramphenicol. J Infect 1983; 6: 29–32.
18. de Francisco A, Chakraborty J. Adherence to cotrimoxazole treatment for acute lower respiratory tract infections in rural Bangladeshi children. Ann Trop Paediatr 1998; 18: 17–21.
19. Blasi F, Tarsia P. Value of short-course antimicrobial therapy in community-acquired pneumonia. Int J Antimicrob Agents 2005; 26 (Suppl. 3): S148–55.
20. D'Ignazio J, Camere MA, Lewis DE et al. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults. Antimicrob Agents Chemother 2005; 49: 4035–41.
21. File TM, Jr, Mandell LA, Tillotson G et al. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J Antimicrob Chemother 2007; 60: 112–20.
22. Li JZ, Winston LG, Moore DH et al. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 2007; 120: 783–90.
23. Contopoulos-Ioannidis DG, Ioannidis JP, Chew P et al. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J Antimicrob Chemother 2001; 48: 691–703.
24. Agarwal G, Awasthi S, Kabra SK et al. Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial. Bmj 2004; 328: 791.
25. Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial. Lancet 2002; 360: 835–41.
26. el Moussaoui R, de Borgie CA, van den Broek P et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. Bmj 2006; 332: 1355.
27. Peltola H, Vuori-Holopainen E, Kallio MJ. Successful shortening from seven to four days of parenteral beta-lactam treatment for common childhood infections: a prospective and randomized study. Int J Infect Dis 2001; 5: 3–8.
28. Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. Bmj 2005; 330: 456.
29. Marras TK, Nopmaneejumruslers C, Chan CK. Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis. Am J Med 2004; 116: 385–93.
30. Hazir T, Qazi SA, Bin Nisar Y et al. Comparison of standard versus double dose of amoxicillin in the treatment of non-severe pneumonia in children aged 2-59 months: a multi-centre, double blind, randomised controlled trial in Pakistan. Arch Dis Child 2007; 92: 291–7.
31. Hazir T, Qazi SA, Nisar YB et al. Comparison of standard versus double dose of amoxicillin in the treatment of non-severe pneumonia in children aged 2-59 months: A multi-centre, double blind, randomized controlled trial in Pakistan. Arch Dis Child 2006.
32. Clinical efficacy of co-trimoxazole versus amoxicillin twice daily for treatment of pneumonia: a randomised controlled clinical trial in Pakistan. Arch Dis Child 2002; 86: 113–8.
33. Awunor-Renner C. Length of antibiotic therapy in in-patients with primary pneumonias. Ann Trop Med Parasitol 1979; 73: 235–40.
34. Montravers P, Fagon JY, Chastre J et al. Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respir Dis 1993; 147: 38–44.
35. Schouten JA, Prins JM, Bonten MJ et al. Revised SWAB guidelines for antimicrobial therapy of community-acquired pneumonia. Neth J Med 2005; 63: 323–35.
36. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999–2005 гг.: результаты многоцентровых проспективных исследований ПеГАС-I и ПеГАС-II. Клин. микробиол. антимикроб. химиотер. 2006; 8: 33–47.
37. Lynch JP, 3rd, Zhanel GG. Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy. Semin Respir Crit Care Med 2005; 26: 575–616.